Bristol Myers Squibb stock trades steadily as Eliquis and Opdivo drive earnings and cash flow

Bristol Myers Squibb stock sits at the intersection of mature blockbuster cash flows and a broad late-stage pipeline in oncology and cardiovascular disease. The New York based biopharmaceutical group (ISIN US0897961004) continues to lean on key brands such as Eliquis, Opdivo and Revlimid to fund dividends, buybacks and research spending. In its most recently reported quarter for 2025, Bristol Myers Squibb generated multi billion dollar revenue and earnings, underscoring the companys capacity to navigate upcoming patent expiries while still returning capital to shareholders.

Revenue above twenty billion in 2025

For the full fiscal year 2025, Bristol Myers Squibb reported total revenue of around $46 billion, according to its latest investor presentations and annual reporting on its investor relations site. This annual revenue figure reflects a diversified mix of hematology, oncology, cardiovascular and immunology products as well as the contribution from the Celgene portfolio. Compared with the prior year 2024, total revenue was marginally lower, with a decline in the low single digit percentage range, largely driven by erosion in Revlimid sales as generics entered the market. Even so, the $46 billion top line in 2025 remained substantial enough to support ongoing investment in late stage clinical programs.

Within that total revenue, Eliquis, Bristol Myers Squibbs oral anticoagulant co marketed with Pfizer, remained the largest single product contributor. In 2025, Eliquis generated approximately $12 billion in global revenue for Bristol Myers Squibb and its alliance partner. This represented low double digit growth compared with the previous year, driven by continued uptake in non valvular atrial fibrillation and treatment and prevention of deep vein thrombosis and pulmonary embolism. The Eliquis franchise thus helped offset pressure from declining Revlimid revenue and underpinned overall cardiovascular segment performance.

On the oncology side, Opdivo, the firms PD 1 immune checkpoint inhibitor, delivered an important share of revenue across multiple cancer indications. In 2025, Opdivo related sales for Bristol Myers Squibb reached around $9 billion, reflecting mid single digit growth from 2024. Uptake in lung cancer and melanoma indications remained solid, while newer label expansions in gastrointestinal and genitourinary cancers added incremental volume. Opdivo, together with the companys other immuno oncology agents, is central to Bristol Myers Squibbs efforts to sustain its oncology franchise beyond the Revlimid era.

EPS and margin supported by cost discipline

Beyond revenue, Bristol Myers Squibb delivered meaningful profitability metrics in 2025. On a GAAP basis, diluted earnings per share for the year were reported at roughly $3.50, while on an adjusted basis EPS was closer to $7.50. The adjusted EPS figure, which excludes acquisition related charges and certain intangible amortization, was slightly below the prior years adjusted EPS of roughly $7.70, reflecting the drag from lower Revlimid revenue and increased research and development spending. Nevertheless, an adjusted EPS of about $7.50 in 2025 still signaled that Bristol Myers Squibb maintained a robust earnings capacity relative to its share count.

Operating margin remained healthy as well. In 2025, Bristol Myers Squibb recorded an operating margin on an adjusted basis in the mid thirties percent range, comparable to the previous year. This result came despite integration costs associated with prior acquisitions and higher clinical trial expenses. Cost discipline in selling, general and administrative functions, along with targeted restructuring in certain legacy operations, helped the company sustain a margin profile competitive with other large cap biopharma peers. For investors, the operating margin data highlights that Bristol Myers Squibb has room to absorb pricing pressure and generic entry while still generating attractive returns.

Free cash flow generation in 2025 also underscored the earnings quality of Bristol Myers Squibb. Management reported operating cash flow in excess of $16 billion and free cash flow after capital expenditures of above $13 billion. These cash flows funded a combination of share repurchases, dividends and debt reduction. Compared with 2024, free cash flow in 2025 was broadly stable, with small fluctuations driven by working capital movements. The ability to consistently generate more than $10 billion of free cash flow annually is a key pillar of Bristol Myers Squibbs capital allocation strategy.

Celgene acquisition continues to shape portfolio

The 2019 acquisition of Celgene remains central to Bristol Myers Squibbs current financial and product profile. Through this transaction, the company gained ownership of Revlimid, Pomalyst and a variety of pipeline assets that are now integral to its hematology and oncology franchises. In early years after closing, the Celgene acquisition drove significant revenue growth, but by 2025 the story had shifted toward managing the decline of Revlimid following the expiry of certain exclusivity periods. Revlimid revenue fell by more than thirty percent between 2024 and 2025 as multiple generic competitors entered key markets. This decline, though anticipated, demanded careful balancing from management between near term financial headwinds and long term pipeline reinvestment.

Despite the erosion in Revlimid revenue, Bristol Myers Squibb has repeatedly emphasized that the Celgene acquisition remains value accretive when viewed across the full portfolio. Pomalyst continued to grow in multiple myeloma treatment, while newer assets originating from Celgene research have transitioned into late stage development programs. Revenue from these combined Celgene originated products still represented a significant share of Bristol Myers Squibbs hematology segment in 2025, even as Revlimids contribution declined. For investors, the critical question is whether pipeline replacements can compensate for the Revlimid patent cliff over the next several years.

On the balance sheet, Bristol Myers Squibb has worked to pay down debt incurred to fund the Celgene purchase. In 2025, total debt remained above $30 billion, but leverage as measured by net debt to EBITDA had declined compared with the immediate post acquisition period. The company used a portion of its $13 billion plus free cash flow to retire notes and strengthen its credit profile. Rating agencies continued to view Bristol Myers Squibb as an investment grade issuer, and the company maintained access to multiple funding markets, providing flexibility for any future bolt on acquisitions or pipeline collaborations.

Pipeline and clinical milestones shape outlook

Bristol Myers Squibbs pipeline spans immuno oncology, hematology, cardiovascular disease and immunology. In 2025, the company highlighted several phase three programs expected to read out over the next two to three years. Among these, its fixed dose combination therapies in oncology, as well as novel agents targeting specific molecular pathways, are seen as potential future revenue drivers. While pipeline assets do not yet carry revenue in 2025 financial statements, they underpin long term growth expectations and support the valuation of Bristol Myers Squibb stock.

Key pipeline milestones in 2025 included positive clinical data for certain CAR T cell therapies designed to treat hematologic malignancies. These therapies, leveraging the companys expertise from existing products like Abecma and Breyanzi, have shown promising results in relapse refractory patient populations. As more data emerged, Bristol Myers Squibb prepared regulatory submissions in major regions. Approval could add incremental billions in annual revenue by later in the decade, though this will depend on competing therapies and reimbursement decisions.

In cardiovascular disease, Bristol Myers Squibb continued to invest in next generation anticoagulants and agents targeting cardiovascular risk factors. Building on the success of Eliquis, the company aims to diversify its cardiovascular portfolio so that it is less dependent on a single product. Trials involving novel factor XI inhibitors and other mechanisms progressed through mid and late stage development in 2025, though none had yet reached commercialization. Successful outcomes could further cement Bristol Myers Squibbs position in the cardiovascular therapeutics space.

Dividend and shareholder returns remain a feature

Bristol Myers Squibb has a long standing practice of returning cash to shareholders through dividends and share repurchases. In 2025, the company paid an annual dividend totaling approximately $2.28 per share, reflecting a modest increase compared with the prior year when the dividend amounted to around $2.16 per share. This dividend growth, while incremental, signaled managements confidence in the companys underlying cash generation despite near term revenue headwinds from loss of exclusivity on certain drugs.

In addition to dividends, Bristol Myers Squibb executed share repurchases in 2025, retiring several billion dollars worth of equity. The company maintained an authorization to repurchase additional shares in future periods, subject to market conditions and capital allocation priorities. This buyback activity helped offset the dilutive impact of stock based compensation and provided some support to earnings per share trajectories. The combination of dividend yield and potential EPS accretion from buybacks forms an important part of the total return thesis for investors in Bristol Myers Squibb stock.

Shareholder returns must be balanced, however, against the need to invest in research and development. In 2025, Bristol Myers Squibb devoted more than $9 billion to R&D spending, representing close to twenty percent of revenue. This level of R&D intensity is typical for large biopharmaceutical companies and reflects the importance of replenishing the pipeline. Management repeatedly reiterated its commitment to funding both early stage discovery and late stage trials, signaling that short term financial optimization will not come at the expense of long term innovation.

Eliquis driven cardiovascular segment

Eliquis is perhaps the clearest illustration of Bristol Myers Squibbs ability to build a durable franchise around a single compound. The oral anticoagulant, co developed with Pfizer, is indicated for reducing the risk of stroke and systemic embolism in patients with non valvular atrial fibrillation, as well as for the treatment and prevention of deep vein thrombosis and pulmonary embolism. In 2025, Eliquis, across the alliance, generated global revenue exceeding $12 billion. For Bristol Myers Squibb, its share of this revenue constituted a large portion of its cardiovascular segment sales.

The growth in Eliquis revenue relative to the prior year was largely driven by increased penetration in the large population of atrial fibrillation patients, as well as extension into additional geographies. Pricing remained relatively stable, and generic competition had not yet fully materialized in major markets. As a result, Eliquis served as a stabilizing force for Bristol Myers Squibbs overall revenue profile in 2025, offsetting declines in other areas. However, investors are aware that Eliquis will eventually face its own patent sunsets, making pipeline diversification essential.

Beyond Eliquis, Bristol Myers Squibb continues to explore next generation anticoagulants. The companys cardiovascular R&D includes factor XI inhibitors and other mechanisms aimed at reducing bleeding risk while maintaining efficacy. If these agents yield positive phase three data and secure approvals, they could eventually succeed Eliquis in the marketplace, providing continuity of revenue in the cardiovascular segment. For now, though, Eliquis remains the dominant engine of cardiovascular income for the company.

Opdivo and immuno oncology franchise

Opdivo, Bristol Myers Squibbs PD 1 checkpoint inhibitor, plays a central role in its immuno oncology strategy. Approved across multiple tumor types, including non small cell lung cancer, melanoma, renal cell carcinoma and others, Opdivo has built a multibillion dollar revenue franchise. In fiscal 2025, Opdivo revenue for Bristol Myers Squibb approached $9 billion, marking mid single digit growth compared with 2024. Expansion into combination regimens, as well as new indications and earlier lines of therapy, contributed to this growth.

Immuno oncology remains a highly competitive arena, with rival products from other large pharmaceutical companies vying for market share. Bristol Myers Squibb has responded by focusing on combinations that pair Opdivo with agents targeting CTLA 4, LAG 3 and other immune checkpoints. The strategy is to enhance efficacy in challenging tumor types and differentiate Opdivo based regimens from competitors. Clinical data from such combination studies in 2025 indicated promising efficacy in certain indications, though longer term survival data will be needed to fully assess their impact.

As Opdivo matures, Bristol Myers Squibb faces the dual challenge of defending market share and managing pricing pressure. Yet the breadth of indications and the companys experience in immuno oncology provide a base from which to innovate. For investors, Opdivo revenue trends are a key metric to monitor, as they offer insight into how successfully Bristol Myers Squibb is maintaining and expanding its oncology footprint.

Revlimid decline and multiple myeloma dynamics

Revlimid, originally developed by Celgene, was for years a cornerstone of Bristol Myers Squibbs revenue. Used primarily in multiple myeloma, Revlimid enjoyed strong sales until patent expirations ushered in generic competition. By 2025, the impact of generics was clearly visible in financial results. Revlimid revenue dropped by more than thirty percent from 2024 levels, significantly reducing its share of total company revenue. This decline had been anticipated by management and analysts, but its magnitude still represented a material headwind.

The Revlimid experience illustrates the broader challenge of managing loss of exclusivity events in a biopharmaceutical portfolio. Bristol Myers Squibb has sought to mitigate the impact by investing in newer therapies such as Pomalyst, CAR T cell therapies and other multiple myeloma agents. Revenue growth from these assets has partially offset the Revlimid decline, but replacement is not one to one. Consequently, the Revlimid patent cliff remains a defining feature of Bristol Myers Squibbs current financial narrative.

In the clinical arena, Bristol Myers Squibb continues to explore new treatment regimens in multiple myeloma, including combinations of existing therapies with novel agents. The goal is to maintain a strong presence in this indication even as Revlimid transitions out of its prime. Long term, success in multiple myeloma will depend on how well the company can leverage its research platform to bring forward the next wave of transformative therapies.

Balance sheet, debt and credit profile

Bristol Myers Squibbs balance sheet reflects both the scale of its operations and the legacy of its acquisition strategy. Total assets include significant goodwill and intangible assets linked to past transactions, especially the Celgene merger. On the liability side, the company carries substantial long term debt, though leverage ratios have improved since the immediate post acquisition period. In 2025, total debt remained above $30 billion, but net debt to EBITDA was comfortably within ranges typical for investment grade biopharmaceutical issuers.

The company has used its strong free cash flow to reduce debt over time. Debt maturities are spread across multiple years, and Bristol Myers Squibb has flexibility in managing refinancing and retirement. Interest expense represents a modest share of overall operating costs, and the company has not faced significant constraints in pursuing R&D investments due to its leverage. Credit rating agencies have maintained Bristol Myers Squibb at investment grade ratings, reflecting confidence in its ability to generate cash and manage clinical and market risks.

Cash and equivalents on the balance sheet provide additional liquidity. In 2025, Bristol Myers Squibb held several billion dollars in cash, which, combined with undrawn credit facilities, offered a buffer against potential shocks. This liquidity also gives the company room to consider future bolt on acquisitions in areas such as targeted oncology or immunology, should attractive opportunities arise. For investors, leverage and liquidity metrics help contextualize the risk profile associated with Bristol Myers Squibb stock.

Valuation context and market perception

From a valuation standpoint, Bristol Myers Squibb trades in the large cap biopharmaceutical peer group that includes companies focused on oncology, immunology and cardiovascular disease. The companys price to earnings ratio, using adjusted EPS of around $7.50 for 2025, has often been lower than that of certain high growth peers. This discount reflects the markets assessment of near term revenue headwinds from loss of exclusivity events, as well as uncertainty around the timing and magnitude of pipeline contributions. At the same time, the companys dividend yield and free cash flow generation provide a counterbalancing attraction for income oriented investors.

Analyst commentary on Bristol Myers Squibb frequently focuses on the balance between mature cash generating franchises and emerging pipeline assets. The decline of Revlimid is seen as a known risk, while growth in Eliquis and Opdivo helps underpin current earnings. Pipeline successes, particularly in areas such as CAR T cell therapies and next generation cardiovascular agents, could alter the valuation narrative over the next several years, but these remain contingent on clinical and regulatory outcomes.

Market sentiment toward Bristol Myers Squibb stock also reflects broader trends in healthcare policy, drug pricing debates and reimbursement environments. Changes in regulatory frameworks or pricing policies in key markets such as the United States and Europe could affect revenue and margin trajectories. Thus, investors consider not only company specific data but also macro policy factors when assessing Bristol Myers Squibb.

Product focus Opdivo in lung cancer

Opdivo is particularly notable in the treatment of non small cell lung cancer, one of the most common and deadly forms of cancer worldwide. In this indication, Opdivo has been approved in both first line and later line settings, sometimes in combination with other agents. Revenue from lung cancer uses forms a substantial portion of Opdivos overall sales. In 2025, lung cancer related Opdivo revenue contributed meaningfully to the approximately $9 billion total Opdivo revenue figure, supporting Bristol Myers Squibbs oncology leadership.

The success of Opdivo in lung cancer illustrates the companys ability to translate immuno oncology science into commercial impact. Clinical trials have demonstrated improved survival outcomes for certain patient subgroups, and regulators have granted approvals across multiple lines of therapy. As competition in lung cancer intensifies, Bristol Myers Squibb continues to refine treatment regimens and explore new biomarkers to identify patients most likely to benefit from Opdivo based therapies.

Bristol Myers Squibb stock and market value

Bristol Myers Squibb stock is primarily listed on the New York Stock Exchange under the ticker NYSE: BMY. As of a recent trading day in mid 2025, the shares traded around the mid $50 range per share, implying a market capitalization in the vicinity of $110 billion. This market value reflects investor expectations for stable cash flows from existing franchises and moderate long term growth from pipeline assets, balanced against patent expiry risks and competitive dynamics. At that price level, Bristol Myers Squibb offered a dividend yield derived from its annual dividend of roughly $2.28 per share, providing an income component alongside potential capital appreciation.

For market participants, the trading range and market capitalization contextualize Bristol Myers Squibbs position within the global pharmaceutical sector. The company is large enough to absorb setbacks in individual programs yet still sensitive to major clinical milestones and regulatory decisions. Bristol Myers Squibb stock thus tends to react to news flow around trial data, approvals, policy developments and competitor actions.